Literature DB >> 7680170

Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation.

R Mañez1, L T White, S Kusne, M Martin, A J Demetris, T E Starzl, R J Duquesnoy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7680170      PMCID： PMC2956276     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  7 in total

Review 1.  Relevance of immune responses to pathogenesis of cytomegalovirus-associated diseases.

Authors:  R C Gehrz; Y N Liu; J Eckhardt; A Klaus
Journal:  Transplant Proc       Date:  1991-06       Impact factor: 1.066

2.  A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

Authors:  J Fung; K Abu-Elmagd; A Jain; R Gordon; A Tzakis; S Todo; S Takaya; M Alessiani; A Demetris; O Bronster
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients.

Authors:  G V Quinnan; N Kirmani; A H Rook; J F Manischewitz; L Jackson; G Moreschi; G W Santos; R Saral; W H Burns
Journal:  N Engl J Med       Date:  1982-07-01       Impact factor: 91.245

4.  Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect?

Authors:  B H Markus; R J Duquesnoy; R D Gordon; J J Fung; M Vanek; G Klintmalm; C Bryan; D Van Thiel; T E Starzl
Journal:  Transplantation       Date:  1988-09       Impact factor: 4.939

5.  Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation.

Authors:  P T Donaldson; G J Alexander; J O'Grady; J Neuberger; B Portmann; M Thick; H Davis; R Y Calne; R Williams
Journal:  Lancet       Date:  1987-04-25       Impact factor: 79.321

6.  Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients.

Authors:  A J Demetris; J J Fung; S Todo; J McCauley; A Jain; S Takaya; M Alessiani; K Abu-Elmagd; D H Van Thiel; T E Starzl
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

7.  Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation.

Authors:  J G O'Grady; G J Alexander; S Sutherland; P T Donaldson; F Harvey; B Portmann; R Y Calne; R Williams
Journal:  Lancet       Date:  1988-08-06       Impact factor: 79.321
  7 in total
  3 in total

1.  Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.

Authors:  A Jain; A J Demetris; R Kashyap; K Blakomer; K Ruppert; A Khan; S Rohal; T E Starzl; J J Fung
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

Review 2.  The liver allograft, chronic (ductopenic) rejection, and microchimerism: what can they teach us?

Authors:  A J Demetris; N Murase; C P Delaney; M Woan; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

3.  Cytomegalovirus infection and proinflammatory cytokine activation modulate the surface immune determinant expression and immunogenicity of cultured murine extrahepatic bile duct epithelial cells.

Authors:  H Y Hsu; M H Chang; Y H Ni; S F Huang
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.